Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Among authors: cheng y. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
Reply.
Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Clark WL, et al. Among authors: cheng y. Ophthalmology. 2016 Oct;123(10):e60-1. doi: 10.1016/j.ophtha.2016.03.020. Ophthalmology. 2016. PMID: 27664917 No abstract available.
Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
Heissigerová J, Callanan D, de Smet MD, Srivastava SK, Karkanová M, Garcia-Garcia O, Kadayifcilar S, Ozyazgan Y, Vitti R, Erickson K, Athanikar A, Chu K, Saroj N, Sundaram PA, Varona R, Corp-Dit-Genti V, Buggage R, Cheng Y, Soo Y, Nguyen QD. Heissigerová J, et al. Among authors: cheng y. Ophthalmology. 2019 Mar;126(3):428-437. doi: 10.1016/j.ophtha.2018.09.044. Epub 2018 Oct 11. Ophthalmology. 2019. PMID: 30316888 Clinical Trial.
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, Berliner AJ, Chu K, Cheng Y, Boyer DS. Khurana RN, et al. Among authors: cheng y. Am J Ophthalmol. 2019 Apr;200:161-168. doi: 10.1016/j.ajo.2019.01.005. Epub 2019 Jan 19. Am J Ophthalmol. 2019. PMID: 30664844 Clinical Trial.
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Brown DM, et al. Among authors: cheng y. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. JAMA Ophthalmol. 2021. PMID: 34351414 Free PMC article. Clinical Trial.
29,194 results
You have reached the last available page of results. Please see the User Guide for more information.